KRAS and metastatic colorectal cancer: Lapatinib and cetuximab can be used as a reference for the treatment of KRAS wild-type, HER2-positive metastatic colorectal cancer in a long-term clinical trial (Ma et al. 2021a; Tosi et al. 2020).